계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Jazz Pharmaceuticals
About
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
- Palo Alto,California,United States
- 501 - 1000
- https://www.jazzpharma.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $6.99M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- nasdaq:JAZZ
- Legal Name
- Jazz Pharmaceuticals, Inc.
- Also Known As
- Jazz Pharmaceuticals plc
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 22, 2021 | Post-IPO Debt | $1.50B | — | — | — | Detail |
| Dec 7, 2009 | Post-IPO Debt | $120M | — | — | — | Detail |
| Jul 8, 2009 | Post-IPO Equity | $6.99M | 1 |
Longitude Capital
|
— | Detail |
| May 8, 2008 | Post-IPO Equity | $75M | 1 | — | — | Detail |
| May 31, 2007 | IPO | $108M | — | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 31, 2021
Casa
|
Series A | $21M | Bitcoin | — |
|
Jul 29, 2021
Onera Health
|
Series B | €10.50M | Health Diagnostics | — |
|
Jul 29, 2021
Onera Health
|
Series B | €10.50M | Health Care | — |
|
Apr 24, 2019
Onera Health
|
Series A | €8.16M | Health Care | Yes |
|
Apr 23, 2019
Onera Health
|
Series A | $9.30M | Health Diagnostics | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Longitude Capital
|
Yes | Post-IPO Equity |
Kohlberg Kravis Roberts
|
Yes | Series B |
Kingsbridge Capital
|
— | Post-IPO Equity |
Adams Street Partners
|
— | Series B |
Beecken Petty O'Keefe & Company
|
— | Series B |
EGS Healthcare Capital Partners
|
— | Series B |
|
|
— | Series B |
|
|
— | Series B |
Prospect Venture Partners
|
— | Series B |
Thoma Cressey Equity Partners
|
— | Series B |
Employee Profiles
Acquisition
Jazz Pharmaceuticals has acquired 9 organizations. Their most recent acquisition was Orphan Medical on Apr 19, 2005. They acquired Orphan Medical for $122.60M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Apr 19, 2005
|
Health Care | acquisition | $ 122.60M | Detail |
|
Sep 19, 2011
Azur Pharma
|
Biotechnology | acquisition | — | Detail |
|
Apr 26, 2012
EUSA Pharma
|
Biotechnology | — | $ 650M | Detail |
|
Dec 19, 2013
Gentium
|
Biotechnology | — | — | Detail |
|
May 11, 2016
Amolyt Pharma
|
Biotechnology | acquisition | $ 20.50M | Detail |
